Sacha Gnjatic

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/308035/publications.pdf

Version: 2024-02-01

238	28,421	11608	6113
papers	citations	70 h-index	159 g-index

269	269	269	37996
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. Science Translational Medicine, 2022, 14, eabm7853.	5.8	71
2	Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 219-229.	3.7	79
3	Spatial CRISPR genomics identifies regulators of the tumor microenvironment. Cell, 2022, 185, 1223-1239.e20.	13.5	79
4	Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery. Nature Medicine, 2022, 28, 626-629.	15.2	12
5	Neutralizing Anti-Granulocyte Macrophage-Colony Stimulating Factor Autoantibodies Recognize Post-Translational Glycosylations on Granulocyte Macrophage-Colony Stimulating Factor Years Before Diagnosis and Predict Complicated Crohnâ€™s Disease. Gastroenterology, 2022, 163, 659-670.	0.6	18
6	Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR. Nature Biotechnology, 2022, 40, 1680-1689.	9.4	29
7	Abstract CT108: Immunogenicity of Poly-ICLC matured dendritic cells as an adjuvant for NY-ESO-1 and Melan-A-MART-1 peptide vaccination compared to MontanideÂ® ISA-51 VG, in study subjects with melanoma in complete clinical remission but at high risk of disease recurrence. Cancer Research, 2022, 82, CT108-CT108.	0.4	2
8	Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab Â± ipilimumab.. Journal of Clinical Oncology, 2022, 40, 9044-9044.	0.8	0
9	A multiplexed immunohistochemical consecutive staining on single slide (MICSSS) analysis of the immune microenvironment of bile duct cancers (BDC) pre and post neoadjuvantchemotherapy (NACT).. Journal of Clinical Oncology, 2022, 40, e16151-e16151.	0.8	1
10	High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 853-862.	0.2	3
11	A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 2470-2480.	3.2	51
12	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology, 2021, 18, 345-362.	12.5	646
13	A streamlined whole blood <scp>CyTOF</scp> workflow defines a circulating immune cell signature of <scp>COVID</scp>â€19. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 446-461.	1.1	28
14	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood, 2021, 137, 3212-3217.	0.6	24
15	Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Modern Pathology, 2021, 34, 1456-1467.	2.9	184
16	Myeloid Cellâ€“associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. Clinical Cancer Research, 2021, 27, 4287-4300.	3.2	42
17	Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy. , 2021, 9, e002392.		9
18	BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nature Medicine, 2021, 27, 851-861.	15.2	38

#	Article	IF	Citations
19	Fr492 SIGNIFICANTLY REDUCED MORTALITY IN COVID-19 PATIENTS WITH GASTROINTESTINAL MANIFESTATIONS. Gastroenterology, 2021, 160, S-330.	0.6	0
20	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. Gastroenterology, 2021, 160, 2435-2450.e34.	0.6	118
21	Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies. Translational Lung Cancer Research, 2021, 10, 3079-3092.	1.3	6
22	Abstract LB048: An adjuvant personalized neoantigen peptide vaccine for the treatment of malignancies (PGV-001). Cancer Research, 2021, 81, LB048-LB048.	0.4	1
23	Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. Clinical Cancer Research, 2021, 27, 5072-5083.	3.2	10
24	Abstract CT182: Neoadjuvant cemiplimab demonstrates complete pathological responses in hepatocellular carcinoma. Cancer Research, 2021, 81, CT182-CT182.	0.4	3
25	Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. Clinical Cancer Research, 2021, 27, 5062-5071.	3.2	8
26	Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. Gastroenterology, 2021, 161, 715-718.e4.	0.6	102
27	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freundâ€™s adjuvant (IFA) for resected high-risk melanoma. , 2021, 9, e003220.		20
28	Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children. Nature Communications, 2021, 12, 4854.	5.8	42
29	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clinical Cancer Research, 2021, 27, 5038-5048.	3.2	13
30	Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. Cancer Cell, 2021, 39, 1442-1444.	7.7	62
31	CTIM-09. PHASE I STUDY OF PD-L1 INHIBITION WITH AVELUMAB AND LASER INTERSTITIAL THERMAL THERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi51-vi51.	0.6	2
32	Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Commpass Study. Blood, 2021, 138, 2691-2691.	0.6	0
33	Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study. Journal of Physical Education and Sports Management, 2020, 6, a004762.	0.5	8
34	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. Clinical Cancer Research, 2020, 26, 450-464.	3.2	62
35	Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. Cancer Immunology Research, 2020, 8, 70-80.	1.6	47
36	Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell, 2020, 183, 982-995.e14.	13.5	440

#	Article	IF	Citations
37	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. Journal of Hematology and Oncology, 2020, 13, 94.	6.9	107
38	Proliferation of HIV-infected renal epithelial cells following virus acquisition from infected macrophages. Aids, 2020, 34, 1581-1591.	1.0	17
39	Sampling the host response to SARS-CoV-2 in hospitals under siege. Nature Medicine, 2020, 26, 1157-1158.	15.2	27
40	400 GM-CSF AUTOANTIBODIES PRECEDE THE DEVELOPMENT OF CROHN'S DISEASE AND PREDICT COMPLICATED PHENOTYPE AT DIAGNOSIS. Gastroenterology, 2020, 158, S-74.	0.6	4
41	Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume Iâ€"conceptual challenges. , 2020, 8, e001389.		7
42	An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature Medicine, 2020, 26, 1636-1643.	15.2	1,860
43	Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume IIâ€"practical challenges. , 2020, 8, e001472.		4
44	A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. OncoImmunology, 2020, 9, 1847846.	2.1	22
45	The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. , 2020, 8, e000155.		140
46	Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City. Clinical Infectious Diseases, 2020, 71, 2933-2938.	2.9	189
47	MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. European Radiology, 2020, 30, 3759-3769.	2.3	97
48	A Common Pituitary Autoantibody in Two Patients with Immune Checkpoint Inhibitor-Mediated Hypophysitis: ZCCHC8. AACE Clinical Case Reports, 2020, 6, e151-e160.	0.4	8
49	Multiplexed Immunohistochemical Consecutive Staining on Single Slide (MICSSS): Multiplexed Chromogenic IHC Assay for High-Dimensional Tissue Analysis. Methods in Molecular Biology, 2020, 2055, 497-519.	0.4	35
50	CIMAC-CIDC tissue imaging harmonization.. Journal of Clinical Oncology, 2020, 38, 3125-3125.	0.8	1
51	Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer. Oncotarget, 2020, 11, 2669-2683.	0.8	14
52	A phase II study of atezolizumab and cobimetinib in PD-1/PD-L1 inhibitor resistant or refractory non-small cell lung cancer: ETCTN #10166.. Journal of Clinical Oncology, 2020, 38, TPS9638-TPS9638.	0.8	1
53	CD3 and CD20 immune cell densities in primary tumors, lymph node metastasis, and recurrent disease samples of head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 6551-6551.	0.8	1
54	CIMAC-CIDC CyTOF harmonization.. Journal of Clinical Oncology, 2020, 38, e15242-e15242.	0.8	1

#	Article	IF	Citations
55	Abstract 3381: Identifying tumor antigen-specific CD4+ T cell dysfunctional states by single cell transcriptomics in immunotherapy-treated cancer patients. , 2020, , .		0
56	Abstract CT231: Clinical study of the safety and tolerability of laser interstitial thermal therapy and avelumab for recurrent glioblastoma. Cancer Research, 2020, 80, CT231-CT231.	0.4	1
57	510. Elevated IL-1Î² level as a predictor of inflammation and death in COVID-19. Open Forum Infectious Diseases, 2020, 7, S320-S321.	0.4	0
58	Integrated Cytof, Scrna-Seq and Cite-Seq Analysis of Bone Marrow Immune Microenvironment in the Mmrf Commpass Study. Blood, 2020, 136, 28-29.	0.6	2
59	Architecture of Sample Preparation and Data Governance of Immuno-Genomic Data Collected from Bone Marrow and Peripheral Blood Samples Obtained from Multiple Myeloma Patients. Blood, 2020, 136, 17-18.	0.6	1
60	289â€…PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting. , 2020, , .		0
61	Identification and Validation of CD138- Multiple Myeloma Immune and Tumor Subpopulations Using Cross Center Scrna-Seq Data. Blood, 2020, 136, 15-15.	0.6	0
62	Characterization of Plasma and Immune Cells Molecular Landscape That Play a Role in Rapid Progression of Multiple Myeloma Using Cross Center Scrna-Seq Study. Blood, 2020, 136, 6-8.	0.6	0
63	Single-Cell Analysis of Crohnâ€™s Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy. Cell, 2019, 178, 1493-1508.e20.	13.5	519
64	First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clinical Cancer Research, 2019, 25, 5808-5817.	3.2	66
65	First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1. Cancer Immunology, Immunotherapy, 2019, 68, 1211-1222.	2.0	22
66	Host tissue determinants of tumour immunity. Nature Reviews Cancer, 2019, 19, 215-227.	12.8	150
67	Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccineâ€“Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma. Cancer Immunology Research, 2019, 7, 658-669.	1.6	12
68	Single-cell immune landscape of human atherosclerotic plaques. Nature Medicine, 2019, 25, 1576-1588.	15.2	540
69	Immunohistochemical Detection of Î³Î´ T Lymphocytes in Formalin-fixed Paraffin-embedded Tissues. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 581-583.	0.6	31
70	A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.. Journal of Clinical Oncology, 2019, 37, 9538-9538.	0.8	3
71	Phase I study of PD-L1 inhibition with avelumab and laser interstitial thermal therapy in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2019, 37, TPS2074-TPS2074.	0.8	3
72	Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis. Oncotarget, 2019, 10, 7142-7155.	0.8	42

#	Article	IF	Citations
73	Abstract IA34: Mapping immune recognition of non-self neoantigens in human pancreatic cancer. , 2019, , .		0
74	Abstract A005: A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers. , 2019, , .		0
75	Abstract IA31: Measuring the emergence of non-self in tumors. , 2019, , .		0
76	Abstract B088: Mapping tumoral and immune heterogeneity in PD-1 responsive glioblastoma. , 2019, , .		0
77	Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy. Blood, 2019, 134, 3093-3093.	0.6	0
78	Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma. Blood, 2019, 134, 4367-4367.	0.6	0
79	High Dimensional Immune Profiling in Smoldering Multiple Myeloma Identifies Novel Organizing Features of the Tumor Microenvironment. Blood, 2019, 134, 4384-4384.	0.6	0
80	Abstract 2528: Mapping tumoral and immune heterogeneity in PD-1 responsive glioblastoma. , 2019, , .		0
81	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. European Urology, 2018, 73, 751-759.	0.9	99
82	IMMU-60. MAPPING TUMORAL AND IMMUNE HETEROGENEITY IN PD-1 RESPONSIVE GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi135-vi135.	0.6	0
83	Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nature Medicine, 2018, 24, 1845-1851.	15.2	626
84	Abstract 5639: Changes in local and peripheral T cell diversity after HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer. , 2018, , .		1
85	A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission.. Journal of Clinical Oncology, 2018, 36, 5553-5553.	0.8	5
86	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists for resected stage IIB-IV melanoma.. Journal of Clinical Oncology, 2018, 36, e15171-e15171.	0.8	2
87	Abstract 1318: Mapping tumoral and immune heterogeneity in PD-1 responsive glioblastoma multiforme. , 2018, , .		0
88	NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecologic Oncology, 2017, 145, 420-425.	0.6	61
89	Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell, 2017, 169, 750-765.e17.	13.5	937
90	Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging. Scientific Reports, 2017, 7, 2452.	1.6	70

#	Article	IF	Citations
91	First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. Journal of Immunotherapy, 2017, 40, 302-306.	1.2	51
92	From local to global. Nature Nanotechnology, 2017, 12, 840-841.	15.6	10
93	NY-ESO-1 is associated with an aggressive phenotype of ovarian cancer. Gynecologic Oncology, 2017, 145, 30.	0.6	0
94	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 2017, 551, 512-516.	13.7	854
95	Immunotherapy biomarkers 2016: overcoming the barriers. , 2017, 5, 29.		21
96	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181
97	Phase II Evaluation of an Allogeneic Tumor Cell Lysate Vaccine with or without Metronomic Oral Cyclophosphamide and Celecoxib in Patients with Thoracic Malignancies. Journal of the American College of Surgeons, 2017, 225, e10.	0.2	0
98	Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS).. Journal of Clinical Oncology, 2017, 35, 11006-11006.	0.8	14
99	Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients.. Journal of Clinical Oncology, 2017, 35, 3090-3090.	0.8	4
100	A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers.. Journal of Clinical Oncology, 2017, 35, TPS3114-TPS3114.	0.8	4
101	DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC).. Journal of Clinical Oncology, 2017, 35, 300-300.	0.8	7
102	MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. Oncotarget, 2017, 8, 14719-14735.	0.8	21
103	Protein Expression Analysis of Melanocyte Differentiation Antigen TRP-2. American Journal of Dermatopathology, 2016, 38, 201-207.	0.3	8
104	A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF. Gastroenterology, 2016, 151, 710-723.e2.	0.6	51
105	HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. Gynecologic Oncology, 2016, 142, 158-162.	0.6	8
106	Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Immunity, 2016, 44, 924-938.	6.6	857
107	In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. Science Immunology, 2016, 1, aaf6925.	5.6	142
108	Perspectives in immunotherapy: meeting report from the â€œImmunotherapy Bridgeâ€, Napoli, December 5th 2015. , 2016, 4, .		0

#	Article	IF	Citations
109	Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. Head and Neck, 2016, 38, 1008-1016.	0.9	14
110	A multimodal imaging workflow to visualize metal mixtures in the human placenta and explore colocalization with biological response markers. Metallomics, 2016, 8, 444-452.	1.0	18
111	Single-agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1.. Journal of Clinical Oncology, 2016, 34, 3093-3093.	0.8	3
112	Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer.. Journal of Clinical Oncology, 2016, 34, 357-357.	0.8	21
113	Prognostic effects of peripheral and tumor-infiltrating T-cell repertoire diversity in ovarian cancer.. Journal of Clinical Oncology, 2016, 34, 5546-5546.	0.8	0
114	Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Scientific Reports, 2015, 5, 14896.	1.6	70
115	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	2.1	119
116	Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma. Cancer Immunology Research, 2015, 3, 278-287.	1.6	81
117	Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity. Frontiers in Immunology, 2015, 6, 67.	2.2	122
118	Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas. Cancer Immunology, Immunotherapy, 2015, 64, 1193-1203.	2.0	18
119	<scp>NYâ€ESO</scp>â€1 specific antibody and cellular responses in melanoma patients primed with <scp>NYâ€ESO</scp>â€1 protein in <scp>ISCOMATRIX</scp> and boosted with recombinant <scp>NYâ€ESO</scp>â€1 fowlpox virus. International Journal of Cancer, 2015, 136, E590-601.	2.3	46
120	The Nonâ€“Small Cell Lung Cancer Immune Contexture. A Major Determinant of Tumor Characteristics and Patient Outcome. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 377-390.	2.5	204
121	Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1.. Journal of Clinical Oncology, 2015, 33, 3021-3021.	0.8	8
122	A first-in-human phase 1 dose-escalating trial of G305 in patients with solid tumors expressing NY-ESO-1.. Journal of Clinical Oncology, 2015, 33, 3073-3073.	0.8	3
123	Impact of gemcitabine + cisplatin + ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC).. Journal of Clinical Oncology, 2015, 33, 4586-4586.	0.8	4
124	Window of opportunity trial of HPV E7 antigen-expressing Listeria-based therapeutic vaccination prior to robotic surgery for HPV-positive oropharyngeal cancer.. Journal of Clinical Oncology, 2015, 33, TPS6088-TPS6088.	0.8	1
125	Poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 VG in patients with melanoma.. Journal of Clinical Oncology, 2015, 33, e14034-e14034.	0.8	0
126	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395

#	Article	IF	Citations
127	Intratumoral checkpoint subversion as a strategy for minimizing adverse effects. OncoImmunology, 2014, 3, e27580.	2.1	2
128	Chemoradiotherapy-Induced Upregulation of PD-1 Antagonizes Immunity to HPV-Related Oropharyngeal Cancer. Cancer Research, 2014, 74, 7205-7216.	0.4	87
129	Cancerâ€“Testis Antigen 7 Expression and Immune Responses Following Allogeneic Stem Cell Transplantation for Multiple Myeloma. Cancer Immunology Research, 2014, 2, 547-558.	1.6	9
130	Nonclassical Antigen-Processing Pathways Are Required for MHC Class IIâ€“Restricted Direct Tumor Recognition by NY-ESO-1â€“Specific CD4+ T Cells. Cancer Immunology Research, 2014, 2, 341-350.	1.6	41
131	Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer. Cancer Immunology Research, 2014, 2, 37-49.	1.6	168
132	Long-term Complete Remission Following Radiosurgery and Immunotherapy in a Melanoma Patient with Brain Metastasis: Immunologic Correlates. Cancer Immunology Research, 2014, 2, 404-409.	1.6	10
133	Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 832-844.	2.5	564
134	Recombinant (rec) MAGE-A3 Protein Immunotherapy and Peripheral Blood Lymphocyte (PBL) Reconstitution Induce Strong Antigen-Specific Humoral and Cellular Immune Responses in Patients Undergoing Autologous Stem Cell Transplantation (ASCT) for Consolidation of Multiple Myeloma (MM). Blood, 2014, 124, 1184-1184.	0.6	7
135	Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma.. Journal of Clinical Oncology, 2014, 32, TPS9119-TPS9119.	0.8	1
136	Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer. PLoS ONE, 2014, 9, e104099.	1.1	65
137	Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.. Journal of Clinical Oncology, 2014, 32, 9086-9086.	0.8	1
138	A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence. Cancer Immunology, Immunotherapy, 2013, 62, 1327-1334.	2.0	2
139	Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein. Clinical Cancer Research, 2013, 19, 6112-6125.	3.2	66
140	The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response. International Journal of Radiation Oncology Biology Physics, 2013, 85, 293-295.	0.4	360
141	Antigen depots: T cell traps?. Nature Medicine, 2013, 19, 397-398.	15.2	5
142	Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial. Cancer Immunology Research, 2013, 1, 340-350.	1.6	62
143	Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients. Cancer Immunology Research, 2013, 1, 235-244.	1.6	109
144	A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. Sarcoma, 2013, 2013, 1-8.	0.7	151

#	Article	IF	Citations
145	Overcoming regulatory Tâ€cell suppression by a lyophilized preparation of Streptococcus pyogenes. European Journal of Immunology, 2013, 43, 989-1000.	1.6	8
146	Ipilimumab for Patients With Advanced Mucosal Melanoma. Oncologist, 2013, 18, 726-732.	1.9	140
147	A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. Cancer Immunity, 2013, 13, 3.	3.2	10
148	Heat Shock Protein 90-Mediated Peptide-Selective Presentation of Cytosolic Tumor Antigen for Direct Recognition of Tumors by CD4+ T Cells. Journal of Immunology, 2012, 188, 3851-3858.	0.4	35
149	Split T-cell tolerance as a guide for the development of tumor antigen-specific immunotherapy. OncoImmunology, 2012, 1, 405-407.	2.1	5
150	Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients. Clinical Cancer Research, 2012, 18, 6497-6508.	3.2	245
151	Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma. Journal of Immunotherapy, 2012, 35, 89-97.	1.2	115
152	Clinical Trial of the Intratumoral Administration of Labeled DC Combined With Systemic Chemotherapy for Esophageal Cancer. Journal of Immunotherapy, 2012, 35, 513-521.	1.2	42
153	Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. Blood, 2012, 119, 3097-3104.	0.6	65
154	Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity. Clinical Cancer Research, 2012, 18, 5449-5459.	3.2	70
155	Therapeutic Administration of a Synthetic CpG Oligodeoxynucleotide Triggers Formation of Anti-CpG Antibodies. Cancer Research, 2012, 72, 4304-4310.	0.4	19
156	Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkinâ€™s lymphoma patients. Cancer Immunology, Immunotherapy, 2012, 61, 2207-2214.	2.0	15
157	Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy. Cancer Research, 2012, 72, 1672-1682.	0.4	46
158	Cancer classification using the Immunoscore: a worldwide task force. Journal of Translational Medicine, 2012, 10, 205.	1.8	676
159	Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma. New England Journal of Medicine, 2012, 366, 925-931.	13.9	1,836
160	Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5797-5802.	3.3	173
161	Heteroclitic serological response in esophageal and prostate cancer patients after NYâ€ESOâ€1 protein vaccination. International Journal of Cancer, 2012, 130, 584-592.	2.3	38
162	NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer. PLoS ONE, 2012, 7, e38783.	1.1	85

#	Article	IF	Citations
163	MAGE-A3 is highly expressed in a subset of colorectal cancer patients. Cancer Immunity, 2012, 12, 16.	3.2	32
164	Integrated NY-ESO-1 antibody and CD8⁺T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16723-16728.	3.3	310
165	Split T Cell Tolerance against a Self/Tumor Antigen: Spontaneous CD4+ but Not CD8+ T Cell Responses against p53 in Cancer Patients and Healthy Donors. PLoS ONE, 2011, 6, e23651.	1.1	15
166	Trypanosoma cruzias an effective cancer antigen delivery vector. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19695-19700.	3.3	48
167	Antibody-Targeted NY-ESO-1 to Mannose Receptor or DEC-205 In Vitro Elicits Dual Human CD8+ and CD4+ T Cell Responses with Broad Antigen Specificity. Journal of Immunology, 2011, 186, 1218-1227.	0.4	98
168	Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy. Cancer Research, 2011, 71, 5670-5677.	0.4	369
169	Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy. Cancer Immunity, 2011, 11, 1.	3.2	9
170	Tumorâ€reactive CD8⁺ Tâ€cell responses after vaccination with NYâ€ESOâ€1 peptide, CpG 7909 and MontanideÂ® ISAâ€51: association with survival. International Journal of Cancer, 2010, 126, 909-918.	2.3	103
171	Toll-Like Receptor Agonists. Cancer Journal (Sudbury, Mass), 2010, 16, 382-391.	1.0	144
172	NYâ€COâ€58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. International Journal of Cancer, 2010, 127, 381-393.	2.3	52
173	Cancer-Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell Carcinomas. Clinical Cancer Research, 2010, 16, 3562-3570.	3.2	51
174	Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3093-3098.	3.3	35
175	Tumor-infiltrating NY-ESO-1â€“specific CD8 ⁺ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7875-7880.	3.3	744
176	Seromic profiling of ovarian and pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5088-5093.	3.3	163
177	Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immunity, 2010, 10, 4.	3.2	35
178	Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immunity, 2010, 10, 1.	3.2	32
179	CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Research, 2009, 37, D816-D819.	6.5	338
180	NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells. Clinical Cancer Research, 2009, 15, 2130-2139.	3.2	74

#	Article	IF	Citations
181	Characterization of Preexisting MAGE-A3-Specific CD4+ T Cells in Cancer Patients and Healthy Individuals and Their Activation by Protein Vaccination. Journal of Immunology, 2009, 183, 4800-4808.	0.4	33
182	Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. Journal of Immunological Methods, 2009, 341, 50-58.	0.6	71
183	Autoantibodies Against Cancer Antigens. Methods in Molecular Biology, 2009, 520, 11-19.	0.4	45
184	Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. Cancer Immunology, Immunotherapy, 2008, 57, 1185-1195.	2.0	22
185	CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20410-20415.	3.3	322
186	Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1. New England Journal of Medicine, 2008, 358, 2698-2703.	13.9	834
187	Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1650-1655.	3.3	149
188	Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant. Journal of Immunology, 2008, 181, 776-784.	0.4	230
189	Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission. Clinical Cancer Research, 2008, 14, 2740-2748.	3.2	98
190	Regulatory T Cellâ€“Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling. Cancer Research, 2008, 68, 5948-5954.	0.4	80
191	RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood, 2008, 111, 1357-1365.	0.6	202
192	Induction of regulatory T cellâ€“resistant helper CD4+ T cells by bacterial vector. Blood, 2008, 111, 1404-1412.	0.6	28
193	Immune Responses Detected in Urothelial Carcinoma Patients After Vaccination With NY-ESO-1 Protein Plus BCG and GM-CSF. Journal of Immunotherapy, 2008, 31, 849-857.	1.2	51
194	Inducing Efficient Cross-priming Using Antigen-coated Yeast Particles. Journal of Immunotherapy, 2008, 31, 607-619.	1.2	15
195	Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12837-12842.	3.3	239
196	CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3967-3972.	3.3	445
197	Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood, 2007, 109, 1103-1112.	0.6	154
198	Immunization With a Recombinant MAGE-A3 Protein After High-dose Therapy for Myeloma. Journal of Immunotherapy, 2007, 30, 847-854.	1.2	37

#	Article	IF	Citations
199	Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination. International Journal of Cancer, 2007, 121, 2042-2048.	2.3	25
200	LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immunity, 2007, 7, 16.	3.2	41
201	Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. Cancer Immunity, 2007, 7, 11.	3.2	71
202	PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. Cancer Immunity, 2007, 7, 18.	3.2	51
203	NYâ€ESOâ€1: Review of an Immunogenic Tumor Antigen. Advances in Cancer Research, 2006, 95, 1-30.	1.9	311
204	Ex-Vivo Analysis of CD8+ T Cells Infiltrating Colorectal Tumors Identifies a Major Effector-Memory Subset with Low Perforin Content. Journal of Clinical Immunology, 2006, 26, 447-456.	2.0	31
205	Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011. International Journal of Cancer, 2006, 118, 668-674.	2.3	11
206	In vitro Stimulation of CD8 and CD4 T Cells by Dendritic Cells Loaded with a Complex of Cholesterol-Bearing Hydrophobized Pullulan and NY-ESO-1 Protein: Identification of a New HLA-DR15â€“Binding CD4 T-Cell Epitope. Clinical Cancer Research, 2006, 12, 1921-1927.	3.2	44
207	Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14453-14458.	3.3	202
208	Influence of CD4+CD25+ Regulatory T Cells on Low/High-Avidity CD4+ T Cells following Peptide Vaccination. Journal of Immunology, 2006, 176, 6340-6346.	0.4	52
209	In vivo antigen delivery by aSalmonella typhimurium type III secretion system for therapeutic cancer vaccines. Journal of Clinical Investigation, 2006, 116, 1946-1954.	3.9	164
210	Host Immune Responses Against CT Antigens in Multiple Myeloma Patients.. Blood, 2006, 108, 3492-3492.	0.6	1
211	Protein and DNA-Based Vaccines With the NY-ESO-1 Antigen in Cancer Patients. Journal of Immunotherapy, 2005, 28, 659.	1.2	1
212	CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood, 2005, 106, 1008-1011.	0.6	160
213	Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18538-18543.	3.3	2,100
214	Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 8055-8062.	3.2	325
215	Immunogenic Targets in Nonâ€“Small Cell Lung Cancer: More Is More. Clinical Cancer Research, 2005, 11, 5331-5332.	3.2	3
216	NY-ESO-1 Expression and Immunogenicity in Esophageal Cancer. Clinical Cancer Research, 2004, 10, 6551-6558.	3.2	62

#	Article	IF	Citations
217	The Spontaneous CD8+ T-Cell Response to HLA-A2-Restricted NY-ESO-1b Peptide in Hepatocellular Carcinoma Patients. Clinical Cancer Research, 2004, 10, 6946-6955.	3.2	65
218	NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors. Cancer Research, 2004, 64, 2199-2204.	0.4	92
219	Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients. Journal of Immunology, 2004, 172, 3289-3296.	0.4	176
220	IFN-Â enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14467-14472.	3.3	36
221	Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10697-10702.	3.3	411
222	Dissecting cytotoxic Tâ€„cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. European Journal of Immunology, 2004, 34, 2919-2929.	1.6	67
223	Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. Cancer Immunity, 2004, 4, 11.	3.2	24
224	Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. Cancer Immunity, 2004, 4, 12.	3.2	19
225	HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones. Cancer Immunity, 2004, 4, 15.	3.2	5
226	Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. Journal of Immunological Methods, 2003, 278, 57-66.	0.6	46
227	Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8862-8867.	3.3	179
228	Cross-Presentation of HLA Class I Epitopes from Exogenous NY-ESO-1 Polypeptides by Nonprofessional APCs. Journal of Immunology, 2003, 170, 1191-1196.	0.4	50
229	NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immunity, 2003, 3, 10.	3.2	28
230	NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Research, 2003, 63, 6076-83.	0.4	191
231	Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immunity, 2003, 3, 19.	3.2	36
232	Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10629-10634.	3.3	78
233	CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11813-11818.	3.3	83
234	Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. Journal of Clinical Investigation, 2002, 110, 1813-1822.	3.9	70

#	Article	IF	Citations
235	Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. Cancer Immunity, 2002, 2, 12.	3.2	14
236	Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL. Journal of Immunology, 2000, 165, 948-955.	0.4	161
237	Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101â€“0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1â€“Expressing Melanoma. Journal of Experimental Medicine, 2000, 191, 625-630.	4.2	196
238	Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. European Journal of Immunology, 1995, 25, 1638-1642.	1.6	34